Stocks · News reference
Craig-Hallum analyst Jason Kreyer initiates coverage on PubMatic (NASDAQ:PUBM) with a Buy rating and announces Price Target of $24.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Partnership brings Sony’s premium CTV inventory to PubMatic’s unified platform, including exclusive opportunities for performance-focused advertisersPubMatic (NASDAQ:PUBM), the leading AI-powered ad tech company
The Trade Desk (TTD) is strengthening its healthcare advertising position through a new integration with OptimizeRx (OPRX), giving advertisers access to authenticated healthcare professional inventory across 400+ EHR systems reaching ~800,000 verified HCPs. The inventory will be available via TTD's OpenPath platform in Q4 2026. This partnership complements TTD's recent expansions with Veeva Crossix and IQVIA Digital, potentially attracting more pharma and life sciences advertisers. However, TTD shares have declined 71.9% over the past year and carry a Zacks Rank #4 (Sell) rating.
B. Riley Securities analyst Naved Khan maintains PubMatic (NASDAQ:PUBM) with a Buy and raises the price target from $17 to $21.